Literature DB >> 23410051

Isolation of antibodies from non-human primates for clinical use.

Arnaud Avril, Jeffrey W Froude, Jacques Mathieu, Thibaut Pelat, Philippe Thullier1.   

Abstract

Antibodies intended for clinical use have been isolated from non-human primates (NHP), chimpanzees (Pan troglodytes) and macaques (Macaca fascicularis and Macaca mulatta), essentially with the use of the phage-display technology. All studies presenting such isolations have been reviewed and presented here, following the main steps of this technology, and advantages and disadvantages of NHP species were analyzed. Optimization of the tolerance of chimeric NHP-human antibodies by germline humanization was mentioned, and the recent alleviation of legal constraints was revealed. The methodology combining the use of phage-displayed libraries built from immunised NHP with germline humanization should be chosen more frequently to develop well-tolerated IgGs, directed against infectious or human antigens.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23410051     DOI: 10.2174/15701638113109990030

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  12 in total

1.  Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques.

Authors:  Thomas Musich; Thorsten Demberg; Ian L Morgan; Jacob D Estes; Genoveffa Franchini; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2015-04-01       Impact factor: 3.969

2.  Structural differences of amyloid-β fibrils revealed by antibodies from phage display.

Authors:  Patrick Droste; André Frenzel; Miriam Steinwand; Thibaut Pelat; Philippe Thullier; Michael Hust; Hilal Lashuel; Stefan Dübel
Journal:  BMC Biotechnol       Date:  2015-06-18       Impact factor: 2.563

3.  Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012.

Authors:  Guillaume Desoubeaux; Arnaud Daguet; Hervé Watier
Journal:  MAbs       Date:  2013-06-07       Impact factor: 5.857

4.  Isolation of a monoclonal antibody from a phage display library binding the rhesus macaque MHC class I allomorph Mamu-A1*001.

Authors:  Nathan Holman; Jason T Weinfurter; Trevor R Harsla; Roger W Wiseman; Aaron J Belli; Anthony J Michaels; Keith A Reimann; Robert I DeMars; Matthew R Reynolds
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

5.  Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E.

Authors:  Sebastian Miethe; Christine Rasetti-Escargueil; Arnaud Avril; Yvonne Liu; Siham Chahboun; Hannu Korkeala; Christelle Mazuet; Michel-Robert Popoff; Thibaut Pelat; Philippe Thullier; Dorothea Sesardic; Michael Hust
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

6.  Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.

Authors:  Arnaud Avril; Sebastian Miethe; Michel R Popoff; Christelle Mazuet; Siham Chahboun; Christine Rasetti-Escargueil; Dorothea Sesardic; Philippe Thullier; Michael Hust; Thibaut Pelat
Journal:  BMC Biotechnol       Date:  2015-09-17       Impact factor: 2.563

Review 7.  Interactions between Autophagy and Bacterial Toxins: Targets for Therapy?

Authors:  Jacques Mathieu
Journal:  Toxins (Basel)       Date:  2015-08-04       Impact factor: 4.546

8.  Human-like antibodies neutralizing Western equine encephalitis virus.

Authors:  Birgit Hülseweh; Torsten Rülker; Thibaut Pelat; Claudia Langermann; Andrè Frenzel; Thomas Schirrmann; Stefan Dübel; Philippe Thullier; Michael Hust
Journal:  MAbs       Date:  2014-02-11       Impact factor: 5.857

9.  Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.

Authors:  Christine Rasetti-Escargueil; Arnaud Avril; Siham Chahboun; Rob Tierney; Nicola Bak; Sebastian Miethe; Christelle Mazuet; Michel R Popoff; Philippe Thullier; Michael Hust; Thibaut Pelat; Dorothea Sesardic
Journal:  MAbs       Date:  2015-09-18       Impact factor: 5.857

Review 10.  The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies.

Authors:  Christine Rasetti-Escargueil; Arnaud Avril; Sebastian Miethe; Christelle Mazuet; Yagmur Derman; Katja Selby; Philippe Thullier; Thibaut Pelat; Remi Urbain; Alexandre Fontayne; Hannu Korkeala; Dorothea Sesardic; Michael Hust; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2017-10-02       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.